On December 10, 2025, InduPro, Inc., a biotechnology company defining membrane protein spatial relationships to create novel therapeutics for the treatment of cancer and autoimmune diseases, announced a strategic equity investment and research collaboration with Sanofi. Wilson Sonsini Goodrich & Rosati advised InduPro on the transaction.

The agreement with Sanofi includes the right of first negotiation for InduPro’s bispecific PD-1 agonist program, which is currently in preclinical development for the treatment of autoimmune and inflammatory disorders. Additionally, InduPro and Sanofi will collaborate on preclinical and IND-enabling research activities with funding from Sanofi, which will also make an undisclosed equity investment in InduPro.

The Wilson Sonsini team that advised InduPro on the transaction included Lowell Segal, Christina Poulsen, Ken Clark, Rachel Slyker, Alex Weber, and Steven Song.

For more information, please see InduPro’s press release. Additional coverage can be found on Fierce Biotech.